Payment for living donor (vendor) kidneys: a cost-effectiveness analysis.
about
ABO incompatible renal transplants: Good or bad?Regulated payments for living kidney donation: an empirical assessment of the ethical concernsOrgan printing: promises and challenges.Paying kidney donors: time to follow Iran?Markets and morals: an experimental survey study.The consequences of public policy to buy and sell organs for transplantation.Should we pay donors to increase the supply of organs for transplantation? No.Insurability of living organ donors: a systematic review.The bioethics and utility of selling kidneys for renal transplantationAssociation of lower costs of pulsatile machine perfusion in renal transplantation from expanded criteria donors.A Cost-Benefit Analysis of Government Compensation of Kidney DonorsThe cost-effectiveness of using payment to increase living donor kidneys for transplantationThe consequences of chronic kidney disease mislabeling in living kidney donorsSaving lives is more important than abstract moral concerns: financial incentives should be used to increase organ donation.A review of the costs and cost effectiveness of interventions in chronic kidney disease: implications for policy.Increasing the pool of deceased donor organs for kidney transplantation.More donors or more delayed graft function? A cost-effectiveness analysis of DCD kidney transplantation.Cost-effective treatment modalities for reducing morbidity associated with chronic kidney disease.Changing Metrics of Organ Procurement Organization Performance in Order to Increase Organ Donation Rates in the United States.Induction therapy with rabbit antithymocyte globulin versus basiliximab after kidney transplantation: a health economic analysis from a German perspective.Effectiveness of an Evidence-Based Induction Therapy Protocol Revision in Adult Kidney Transplant Recipients.Should we pay donors to increase the supply of organs for transplantation? Yes.The Changing Financial Landscape of Renal Transplant Practice: A National Cohort Analysis.Lifetime cost-effectiveness of calcineurin inhibitor withdrawal after de novo renal transplantation.Shortened length of stay improves financial outcomes in living donor kidney transplantation.Cost-benefit of steroid avoidance in renal transplant patients: a prospective randomized study.Attitudes toward live donor kidney transplantation and its commercialization.Consequences of eliminating HLA-B in deceased donor kidney allocation to increase minority transplantation.Surgical challenges in transplantation: the Fourth Annual American Society of Transplant Surgeons' State-of-the-Art Winter Symposium.Potential yield of imminent death kidney donation.Reassessing the Likely Harms to Kidney Vendors in Regulated Organ Markets.Ethical issues regarding related and nonrelated living organ donors.The best argument against kidney sales fails.Incentivizing deceased organ donation: a Swedish priority-setting perspective.Kidney Sales and Market Regulation: A Reply to Semrau.Emergence of an Israel faith-based community organization facilitating live donor kidney transplantation.Response to Open Peer Commentaries on “Assessing the Likely Harms to Kidney Vendors in Regulated Organ Markets”
P2860
Q28236829-CFDE5B96-2076-4F39-A938-C81C217BC24EQ33832332-21DF8096-7D55-43B7-A376-7215204ED449Q34729579-5CDD15AD-FCD1-4D72-925C-9FBA0CEEFF3BQ34784663-3A3E6F60-F174-4880-9599-91EA0012606DQ35648551-7F57EFC9-D096-4387-B30E-1978DAE36B80Q35671640-CF2C9ECD-08C8-413A-B146-BD1D71E4D412Q36718686-16E46894-3781-4649-B35B-CB9A64BBC15DQ36789984-A4E349B7-4658-4C08-9369-6BA828ED5E02Q36824155-5894ACA3-533D-4737-888A-1D5540BC2B19Q37000975-77013B8E-C85B-4254-AE96-ED7683737E86Q37325891-7D41C97A-F7E1-4149-961B-C2F559005B49Q37359048-E672BCD4-294F-4ACB-948E-5CD28ED77FDAQ37394983-8286AF14-F124-45E6-8058-270BB6E75521Q37397909-1F674E94-C940-4014-BA9D-382888E0DE5DQ37889260-8127D07A-6E8B-4875-B67E-605F0C50EC77Q37997296-0D72FF4B-FBC2-4B99-B908-74690E76C68AQ38076762-C00CF8B5-919F-4174-B995-B60A05BFAAA5Q38347571-2F8BDE3F-A6AF-4BC3-B3EA-AD31D4B0543BQ38670849-4B76C78A-42FC-4054-8186-2958C8E79D07Q38757281-6BFADB01-EFFC-410C-9A7E-70C68CEDAAD4Q38802439-5720F50A-369E-4E7C-8856-1ED58A0F8D3FQ39136271-3162D80F-E33F-48D6-A67D-C8FCAB53113DQ39450422-6277D981-18F0-479A-BEA0-B3DEF6E136F3Q42078849-88CC16A8-A1CA-4967-BBC8-2D73D6A742E0Q42176840-3965E55D-ED10-4021-A325-3CBBE8D74CF0Q43129498-43379D8D-017D-4542-841A-46818FCA607DQ45930536-1B176E19-D6DF-43DA-A8E1-9F10948CE9B3Q46240038-C916DA74-F5C4-4B66-B7C2-7004C373FB31Q46474392-B1789EB3-0F8B-4F1A-9781-8B83D4820EBCQ47252631-3AE1FF5E-6026-43C6-94FA-35FA0459F3AAQ47578488-F0C557CD-3E14-491B-A341-E1E66570CAF6Q47782484-54F88C78-6571-4170-8FC3-8DB133FEA6D2Q48064584-DB1CE2D3-BE91-47AA-B75F-8AC4DF0CE148Q48159366-19B39A0C-3ABA-4610-ACF7-124FABC0B5B2Q49921623-8B7064A9-CECA-47E9-A473-9F41E8B72CAEQ55479874-4AA4DB27-028C-43BC-9C7A-D09054994A32Q57988869-CFF0B301-59DE-4873-B067-2FE49FF79F69
P2860
Payment for living donor (vendor) kidneys: a cost-effectiveness analysis.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Payment for living donor (vendor) kidneys: a cost-effectiveness analysis.
@ast
Payment for living donor (vendor) kidneys: a cost-effectiveness analysis.
@en
Payment for living donor
@nl
type
label
Payment for living donor (vendor) kidneys: a cost-effectiveness analysis.
@ast
Payment for living donor (vendor) kidneys: a cost-effectiveness analysis.
@en
Payment for living donor
@nl
prefLabel
Payment for living donor (vendor) kidneys: a cost-effectiveness analysis.
@ast
Payment for living donor (vendor) kidneys: a cost-effectiveness analysis.
@en
Payment for living donor
@nl
P2860
P1476
Payment for living donor (vendor) kidneys: a cost-effectiveness analysis.
@en
P2093
Arthur J Matas
Mark Schnitzler
P2860
P304
P356
10.1046/J.1600-6143.2003.00290.X
P407
P577
2004-02-01T00:00:00Z